If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
=== Robin Williamson === Robin Williamson (Jonjo O'Neill) is the chief communications officer at Tender, assisting Whitney in pivoting the company into banking. During the launch of Tender's banking app, Robin clashes with Yasmin over their dueling PR strategies, with Robin preferring a more traditional rollout via tech publications and podcasts, while Yasmin seeks to capitalize on Henry Muck's profile as CEO by booking him a keynote speech. Yasmin's approach wins over Whitney, who promotes Yasmin to head of communications and fires Robin, deeming him too traditional and risk-averse.
=== Mayor of San Salvador === In August 2014, Bukele announced that he would seek election as mayor of San Salvador in the 2015 elections. His candidacy was confirmed by FMLN secretary-general Medardo González on 19 August 2014. Bukele delegated administration of Nuevo Cuscatlán to council member Michelle Sol in February 2015 to focus on his campaign. During his campaign, which was supported by the Salvadoran Progressive Party, FMLN party leadership called Bukele the party's "crown jewel" ("joya de la corona"). Bukele's campaign used catchphrases such as "we have to change history" ("tenemos que cambiar la historia") and "together we will go forward" ("juntos saldremos adelante") to rally support from young voters. His primary opponent was Edwin Zamora, a businessman and Legislative Assembly deputy from ARENA. Bukele led Zamora in opinion polls before the election. He defeated Zamora with 50.38 percent of the vote on 1 March 2015, and took office on 1 May. Bukele appointed a cousin, Hassan, and his half-brother Yamil to administrative positions on the San Salvador municipal council. The appointments were criticized by ARENA and FMLN politicians.
A total solar eclipse occurs at the Moon's descending node of the orbit in North America and Europe. The total eclipse passes over the Arctic, Greenland, Iceland, the Atlantic Ocean and northern Spain. Trump announces that White House Press Secretary Karoline Leavitt will leave the office at the end of the month to spend more time with her family. 2026 Iran war: US media reports that sailors on the Abraham Lincoln attempted to jump overboard owing to poor conditions such as food shortages, a mental health crisis, and broken toilets that affected all crew members, including female soldiers. Pete Hegseth, the US secretary of defense, denounces the sailors as liars. The US eventually opts to send the aircraft carrier USS George Washington to the Middle East to replace the Lincoln, removing its last aircraft carrier in the Pacific. August 13 – The United States sees the first triple execution on the same day, since 2010. August 14 Six people are killed, including the perpetrator, and one person is injured in a mass shooting at three different locations in Missaukee County, Michigan. Trump announces that the US will annex the Strait of Hormuz "pretty soon" after defeating the Iranian regime in the war. 2026 NFL season: The National Football League suspends Atlanta Falcons linebacker James Pearce Jr. for eight games in violation of the league's personal conduct policy after his arrest in February on domestic violence charges. August 15 – The Democratic National Committee votes to approve South Carolina as the first U.S.
{\displaystyle {\begin{array}{rcl}\\{\ce {^{3}_{1}H}}&{\ce {->[12.32\ {\ce {y}}]}}&{\ce {{^{3}_{2}He}+e^{-}}}\\{\ce {^{4}_{1}H}}&{\ce {->[139\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{^{1}_{0}n}}}\\{\ce {^{5}_{1}H}}&{\ce {->[86\ {\ce {ys}}]}}&{\ce {{^{3}_{1}H}+{2_{0}^{1}n}}}\\{}\end{array}}}
He looked pale, delicate and shaky, not his usual robust self: "He was very ill when he got here." After being taken by Reitell to check in at the Chelsea Hotel, Thomas took the first rehearsal of Under Milk Wood. They then went to the White Horse Tavern in Greenwich Village, before returning to the Chelsea Hotel. The next day, Reitell invited him to her apartment, but he declined. They went sightseeing, but Thomas felt unwell and retired to his bed for the rest of the afternoon. Reitell gave him half a grain (32.4 milligrams) of phenobarbitone to help him sleep and spent the night at the hotel with him. Two days later, on 23 October, at the third rehearsal, Thomas said he was too ill to take part, but he struggled on, shivering and burning with fever, before collapsing on the stage. The following day, 24 October, Reitell took Thomas to see her doctor, Milton Feltenstein, who administered cortisone injections and Thomas made it through the first performance that evening, but collapsed immediately afterwards. "This circus out there," he told a friend who had come back-stage, "has taken the life out of me for now." Reitell later said that Feltenstein was "rather a wild doctor who thought injections would cure anything."
Sources: en.wikipedia.org
== See also == Alpha toxin Pathology Lysosomal acid lipase deficiency Peripheral membrane proteins Phospholipase A Phospholipase C Triglyceride lipase Phospholipase A2 Outer membrane phospholipase A1 Patatin-like phospholipase
In anatomy, the meninges (; sing. meninx ; from Ancient Greek μῆνινξ (mêninx) 'membrane') are protective membranes that cover the brain and spinal cord. In mammals, three meninges have been clearly identified: the dura mater, the arachnoid mater, and the pia mater. Each layer has its own molecularly distinct type of fibroblasts. The meninges act as a physical and immunological protective barrier for the brain and spinal cord, shielding the central nervous system (CNS) from injury. They anchor and support the tissues of the CNS, and provide containment for cerebrospinal fluid (CSF) and the arteries and veins that supply blood to the brain and spinal cord. The dura mater surrounds the arachnoid mater and supports the dural sinuses, which carry blood from the brain to the heart. The area between the arachnoid and pia mater is known as the subarachnoid space. It contains cerebrospinal fluid. The arachnoid and pia maters produce prostaglandin D2 synthase, a major cerebrospinal fluid protein. The arachnoid mater provides a restrictive permeability barrier between the cerebrospinal fluid in the subarachnoid space and the circulation of blood in the dura. The pia mater is a thin sheet of connective tissue that interfaces with the glial limitans superficialis.
=== Weekly frequency === In general, more weekly training sessions lead to higher increases in physical strength. However, when training volume was equalized, training frequency had no influence on muscular strength. In addition, greater frequency had no significant effect on single-joint exercises. There may be a fatigue recovery effect in which spreading the same amount of training over multiple days boosts strength gains, but this has to be confirmed by future studies. For muscle growth, a training frequency of two sessions per week had greater effects than once per week. Whether training a muscle group three times per week is superior to a twice-per-week protocol remains to be determined.
=== Body weight === In the short and medium term, people taking a low-carbohydrate diet can experience more weight loss than people taking a low-fat diet. The Endocrine Society stated that "when calorie intake is held constant ... body-fat accumulation does not appear to be affected by even very pronounced changes in the amount of fat vs. carbohydrate in the diet". People on such a diet have very slightly more weight loss initially, equivalent to approximately 100kcal/day, but that advantage diminishes over time and is ultimately insignificant. A Cochrane review from 2022 looked into longer periods of two years and found no benefit for adhering to a low-carbohydrate diet in comparison to balanced diets. Much of the research comparing low-fat vs. low-carbohydrate dieting has been of poor quality and studies which reported large effects have garnered disproportionate attention in comparison to those which are methodologically sound. A 2018 review said "higher-quality meta-analyses reported little or no difference in weight loss between the two diets." Low-quality meta-analyses have tended to report favourably on the effect of low-carbohydrate diets: a systematic review reported that 8 out of 10 meta-analyses assessed whether weight loss outcomes could have been affected by publication bias, and 7 of them concluded positively. A 2017 review concluded that a variety of diets, including low-carbohydrate diets, achieve similar weight loss outcomes, which are mainly determined by calorie restriction and adherence rather than the type of diet.
Sources: en.wikipedia.org
Kinases are part of the larger family of phosphotransferases. Kinases should not be confused with phosphorylases, which catalyze the addition of inorganic phosphate groups to an acceptor, nor with phosphatases, which remove phosphate groups (dephosphorylation). The phosphorylation state of a molecule, whether it be a protein, lipid or carbohydrate, can affect its activity, reactivity and its ability to bind other molecules. Therefore, kinases are critical in metabolism, cell signalling, protein regulation, cellular transport, secretory processes and many other cellular pathways, which makes them very important to physiology.
Automated synthesis or automatic synthesis is a set of techniques that use robotic equipment to perform chemical synthesis using a robotic system run using software control. Automating processes allows for higher efficiency and product quality although automation technology can be cost-prohibitive and there are concerns regarding overdependence and job displacement. Chemical processes were automated throughout the 19th and 20th centuries, with major developments happening in the previous thirty years, as technology advanced. Tasks that are performed may include: synthesis in variety of different conditions, sample preparation, purification, and extractions. Applications of automated synthesis are found on research and industrial scales in a wide variety of fields including polymers, personal care, and radiosynthesis.
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.